Citations (55)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Ruha Shadab, James V. Lavery, SarahAnn M. McFadden, Jad A. Elharake, Fauzia Malik & Saad B. Omer. (2022) Key ethical considerations to guide the adjudication of a single-dose HPV vaccine schedule. Human Vaccines & Immunotherapeutics 18:1.
Read now
Read now
J. Hoes, H. Pasmans, T. M. Schurink-van ’t Klooster, F. R. M. van der Klis, R. Donken, J. Berkhof & H. E. de Melker. (2022) Review of long-term immunogenicity following HPV vaccination: Gaps in current knowledge. Human Vaccines & Immunotherapeutics 18:1.
Read now
Read now
Margaret Stanley. (2019) HPV vaccines: alternative dosage schedules. Expert Review of Vaccines 18:12, pages 1309-1316.
Read now
Read now
Tino F. Schwarz, Li-Min Huang, Alejandra Valencia, Falko Panzer, Cheng-Hsun Chiu, Annabelle Decreux, Sylviane Poncelet, Naveen Karkada, Nicolas Folschweiller, Lan Lin, Gary Dubin & Frank Struyf. (2019) A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years. Human Vaccines & Immunotherapeutics 15:7-8, pages 1970-1979.
Read now
Read now
Robert A. Bednarczyk. (2019) Addressing HPV vaccine myths: practical information for healthcare providers. Human Vaccines & Immunotherapeutics 15:7-8, pages 1628-1638.
Read now
Read now
Alain Bouckenooghe, Fabrice Bailleux & Emmanuel Feroldi. (2019) Modeling the long-term persistence of neutralizing antibody in children and toddlers after vaccination with live attenuated Japanese encephalitis chimeric virus vaccine. Human Vaccines & Immunotherapeutics 15:1, pages 72-79.
Read now
Read now
Xue Chen, Ting Zhang, Hongyang Liu, Yaru Hao, Guoyang Liao & Xuemei Xu. (2018) Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice. Human Vaccines & Immunotherapeutics 14:8, pages 2025-2033.
Read now
Read now
Maria Julieta Germar, Carrie Purugganan, Ma. Socorro Bernardino, Benjamin Cuenca, Y-Chen Chen, Xiao Li, Georges Van Kriekinge & I-Heng Lee. (2017) Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule. Human Vaccines & Immunotherapeutics 13:5, pages 1158-1166.
Read now
Read now
Articles from other publishers (47)
Kahren van Eer, Marit Middeldorp, Tsira Dzebisasjvili, Najima Lamkaraf, Hester E de Melker, Renske D M Steenbergen & Audrey J King. (2023) Effects of 2 and 3 Vaccinations With the Bivalent Human Papillomavirus (HPV) Vaccine on the Prevalence and Load of HPV in Clearing and Persistent Infections in Young Women. The Journal of Infectious Diseases 228:8, pages 1012-1022.
Crossref
Crossref
Vicky Roy, Wonyeong Jung, Caitlyn Linde, Emily Coates, Julie Ledgerwood, Pamela Costner, Galina Yamshchikov, Hendrik Streeck, Boris Juelg, Douglas A. Lauffenburger & Galit Alter. (2023) Differences in HPV-specific antibody Fc-effector functions following Gardasil® and Cervarix® vaccination. npj Vaccines 8:1.
Crossref
Crossref
Emmanuel Timmy Donkoh, Edward Tieru Dassah & Ellis Owusu-Dabo. (2022) Optimization of a protocol for the evaluation of antibody responses to human papillomavirus (HPV) vaccination in low-resource settings. BMC Women's Health 22:1.
Crossref
Crossref
Jingyi Fan, Shengbin Jin, Lachlan Gilmartin, Istvan Toth, Waleed M. Hussein & Rachel J. Stephenson. (2022) Advances in Infectious Disease Vaccine Adjuvants. Vaccines 10:7, pages 1120.
Crossref
Crossref
Fan Wang, Kristen N. Jozkowski & Shengfan Zhang. (2021) Evaluating Risk-Stratified HPV Catch-up Vaccination Strategies: Should We Go beyond Age 26?. Medical Decision Making 42:4, pages 524-537.
Crossref
Crossref
Barbara J. Kuter, Suzanne M. Garland, Anna R. Giuliano & Margaret A. Stanley. (2021) Current and future vaccine clinical research with the licensed 2-, 4-, and 9-valent VLP HPV vaccines: What's ongoing, what's needed?. Preventive Medicine 144, pages 106321.
Crossref
Crossref
Yuemei Hu, Xiang Zhang, Yilin He, Zhilong Ma, Yan Xie, Xiangbin Lu, Yabin Xu, Yanqiu Zhang, Yunyu Jiang, Hui Xiao, Frank Struyf, Nicolas Folschweiller, Johny Jiang, Sylviane Poncelet, Naveen Karkada, Archana Jastorff & Dorota Borys. (2020) Long‐term persistence of immune response to the AS04‐adjuvanted HPV‐16/18 vaccine in Chinese girls aged 9‐17 years: Results from an 8‐9‐year follow‐up phase III open‐label study. Asia-Pacific Journal of Clinical Oncology 16:6, pages 392-399.
Crossref
Crossref
Aimée R Kreimer, Joshua N Sampson, Carolina Porras, John T Schiller, Troy Kemp, Rolando Herrero, Sarah Wagner, Joseph Boland, John Schussler, Douglas R Lowy, Stephen Chanock, David Roberson, Mónica S Sierra, Sabrina H Tsang, Mark Schiffman, Ana Cecilia Rodriguez, Bernal Cortes, Mitchell H Gail, Allan Hildesheim, Paula Gonzalez & Ligia A Pinto. (2020) Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial. JNCI: Journal of the National Cancer Institute 112:10, pages 1038-1046.
Crossref
Crossref
Peter Wnukowski-Mtonga, Sanjay Jayasinghe, Clayton Chiu, Kristine Macartney, Julia Brotherton, Basil Donovan, Madeline Hall, David W Smith, Karen Peterson, Sue Campbell-Lloyd, Christine Selvey, Michelle Giles, John Kaldor & Helen Marshall. (2020) Scientific evidence supporting recommendations on the use of the 9-valent HPV vaccine in a 2-dose vaccine schedule in Australia. Communicable Diseases Intelligence 44.
Crossref
Crossref
Renjie Wang, Wei Pan, Lei Jin, Weiming Huang, Yuehan Li, Di Wu, Chun Gao, Ding Ma & Shujie Liao. (2020) Human papillomavirus vaccine against cervical cancer: Opportunity and challenge. Cancer Letters 471, pages 88-102.
Crossref
Crossref
Julia ML. Brotherton. (2019) Rationalizing the HPV vaccination schedule: A long road to a worthwhile destination. Papillomavirus Research 8, pages 100190.
Crossref
Crossref
Hanna Bergman, Brian S Buckley, Gemma Villanueva, Jennifer Petkovic, Chantelle Garritty, Vittoria Lutje, Alina Ximena Riveros-Balta, Nicola Low & Nicholas Henschke. (2019) Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males. Cochrane Database of Systematic Reviews 2019:11.
Crossref
Crossref
Hella Pasmans, Tessa M. Schurink-van't Klooster, Marjan J.M. Bogaard, Debbie M. van Rooijen, Hester E. de Melker, Marij J.P. Welters, Sjoerd H. van der Burg, Fiona R.M. van der Klis & Anne-Marie Buisman. (2019) Long-term HPV-specific immune response after one versus two and three doses of bivalent HPV vaccination in Dutch girls. Vaccine 37:49, pages 7280-7288.
Crossref
Crossref
Lan Lin, Mercedes Macias Parra, Victor Y. Sierra, Albino Salas Cespedes, Maria Angelica Granados, Adriana Luque, Naveen Karkada, Maria Mercedes Castrejon Alba, Luis Romano-Mazzotti, Dorota Borys & Frank Struyf. (2019) Long-term Immunogenicity and Safety of the AS04-adjuvanted Human Papillomavirus–16/18 Vaccine in Four- to Six-year-old Girls. The Pediatric Infectious Disease Journal 38:10, pages 1061-1067.
Crossref
Crossref
Emad Matanes & Walter H. Gotlieb. (2019) Immunotherapy of gynecological cancers. Best Practice & Research Clinical Obstetrics & Gynaecology 60, pages 97-110.
Crossref
Crossref
C. Raina MacIntyre, Peter J. Shaw, Fiona E. Mackie, Christina Boros, Helen Marshall, Holly Seale, Sean E. Kennedy, Aye Moa, Abrar Ahmad Chughtai, Mallory Trent, Edward V O'Loughlin & Michael Stormon. (2019) Long term follow up of persistence of immunity following quadrivalent Human Papillomavirus (HPV) vaccine in immunocompromised children. Vaccine 37:37, pages 5630-5636.
Crossref
Crossref
Nicolas Folschweiller, Ulrich Behre, Marc Dionne, Paolo Durando, Susanna Esposito, Linda Ferguson, Murdo Ferguson, Peter Hillemanns, Shelly A McNeil, Klaus Peters, Brian Ramjattan, Tino F Schwarz, Khuanchai Supparatpinyo, Pemmaraju V Suryakirian, Michel Janssens, Philippe Moris, Annabelle Decreux, Sylviane Poncelet & Frank Struyf. (2019) Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine. The Journal of Infectious Diseases 219:11, pages 1799-1803.
Crossref
Crossref
Katherine H. Parker, Troy J. Kemp, Kimberly Isaacs-Soriano, Martha Abrahamsen, Yuanji Pan, Eduardo Lazcano-Ponce, Jorge Salmeron, Ligia A. Pinto & Anna R. Giuliano. (2019) HPV-specific antibodies at the oral cavity up to 30 months after the start of vaccination with the quadrivalent HPV vaccine among mid-adult aged men. Vaccine 37:21, pages 2864-2869.
Crossref
Crossref
Eduardo Lazcano-Ponce, Leticia Torres-Ibarra, Aurelio Cruz-Valdez, Jorge Salmerón, Tonatiuh Barrientos-Gutiérrez, Javier Prado-Galbarro, Margaret Stanley, Nubia Muñoz, Rolando Herrero & Mauricio Hernández-Ávila. (2019) Persistence of Immunity When Using Different Human Papillomavirus Vaccination Schedules and Booster-Dose Effects 5 Years After Primary Vaccination. The Journal of Infectious Diseases 219:1, pages 41-49.
Crossref
Crossref
Andreas Chrysostomou, Dora Stylianou, Anastasia Constantinidou & Leondios Kostrikis. (2018) Cervical Cancer Screening Programs in Europe: The Transition Towards HPV Vaccination and Population-Based HPV Testing. Viruses 10:12, pages 729.
Crossref
Crossref
Claudia Robles, María de la Luz Hernández & Maribel Almonte. (2018) Alternative HPV vaccination schedules in Latin America. Salud Pública de México 60:6, nov-dic, pages 693.
Crossref
Crossref
Maryam Dadar, Sandip Chakraborty, Kuldeep Dhama, Minakshi Prasad, Rekha Khandia, Sameer Hassan, Ashok Munjal, Ruchi Tiwari, Kumaragurubaran Karthik, Deepak Kumar, Hafiz M. N. Iqbal & Wanpen Chaicumpa. (2018) Advances in Designing and Developing Vaccines, Drugs and Therapeutic Approaches to Counter Human Papilloma Virus. Frontiers in Immunology 9.
Crossref
Crossref
Tessa M. Schurink-van 't Klooster, Robine Donken, Rutger M. Schepp, Fiona R.M. van der Klis & Hester E. de Melker. (2018) Persistence of immune response following bivalent HPV vaccination: A follow-up study among girls routinely vaccinated with a two-dose schedule. Vaccine 36:49, pages 7580-7587.
Crossref
Crossref
Jessica Yasmine Islam, Alexis M. Hoyt, Silvina Ramos, Karen Morgan, Chan Joo Kim, Sylvia de Sanjose, Nicole Butera, Virginia Senkomago, Karin L. Richter, Mary Anne McDonald, Nadja A. Vielot & Jennifer S. Smith. (2018) Acceptability of two- versus three-dose human papillomavirus vaccination schedule among providers and mothers of adolescent girls: a mixed-methods study in five countries. Cancer Causes & Control 29:11, pages 1115-1130.
Crossref
Crossref
Larysa Kostyuchenko, Natalya Volodko, Andriana Belyak & Oksana Pushkareva. (2018) VACCINATION AGAINST HIGH CARCINOGENIC TYPES OF THE HUMAN PAPILLOMA VIRUS IN THE PREVENTION OF CERVICAL CANCER: REALITIES IN WESTERN UKRAINE. Proceedings of the Shevchenko Scientific Society Medical sciences 52:1, pages 108-116.
Crossref
Crossref
Ligia A. Pinto, Joakim Dillner, Simon Beddows & Elizabeth R. Unger. (2018) Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development. Vaccine 36:32, pages 4792-4799.
Crossref
Crossref
Polona J. Maver & Mario Poljak. (2018) Progress in prophylactic human papillomavirus (HPV) vaccination in 2016: A literature review. Vaccine 36:36, pages 5416-5423.
Crossref
Crossref
Zheng Quan Toh, Kathleen Wen Bei Cheow, Fiona M Russell, Edwin Hoe, Rita Reyburn, James Fong, Evelyn Tuivaga, Felisita T Ratu, Cattram D Nguyen, Silivia Matanitobua, Andrea Reitsma, Sepehr N Tabrizi, Suzanne M Garland, Edward K Mulholland & Paul V Licciardi. (2018) Cellular Immune Responses 6 Years Following 1, 2, or 3 Doses of Quadrivalent HPV Vaccine in Fijian Girls and Subsequent Responses to a Dose of Bivalent HPV Vaccine. Open Forum Infectious Diseases 5:7.
Crossref
Crossref
Marc Arbyn, Lan Xu, Cindy Simoens & Pierre PL Martin-Hirsch. (2018) Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database of Systematic Reviews 2020:3.
Crossref
Crossref
Katherine H. Parker, Troy J. Kemp, Yuanji Pan, Zhen Yang, Anna R. Giuliano & Ligia A. Pinto. (2018) Evaluation of HPV-16 and HPV-18 specific antibody measurements in saliva collected in oral rinses and merocel® sponges. Vaccine 36:19, pages 2705-2711.
Crossref
Crossref
Lan Lin, Mercedes Macias Parra, Victor Y. Sierra, Albino Salas Cespedes, Maria Angelica Granados, Adriana Luque, Silvia Damaso, Maria Mercedes Castrejon Alba, Luis Romano-Mazzotti & Frank Struyf. (2018) Safety and Immunogenicity of the HPV-16/18 AS04-adjuvanted Vaccine in 4–6-year-old Girls. Pediatric Infectious Disease Journal 37:4, pages e93-e102.
Crossref
Crossref
Lenny Zaffaroni & Francesco Peri. (2018) Recent advances on Toll-like receptor 4 modulation: new therapeutic perspectives. Future Medicinal Chemistry 10:4, pages 461-476.
Crossref
Crossref
Lea E. Widdice, Elizabeth R. Unger, Gitika Panicker, Rebecca Hoagland, S. Todd Callahan, Lisa A. Jackson, Andrea A. Berry, Karen Kotloff, Sharon E. Frey, Christopher J. Harrison, Barbara A. Pahud, Kathryn M. Edwards, Mark J. Mulligan, Jon Sudman & David I. Bernstein. (2018) Antibody responses among adolescent females receiving two or three quadrivalent human papillomavirus vaccine doses at standard and prolonged intervals. Vaccine 36:6, pages 881-889.
Crossref
Crossref
John T. Schiller, Lauri E. Markowitz, Allan Hildesheim & Douglas R. Lowy. 2018. Plotkin's Vaccines. Plotkin's Vaccines
430
455.e10
.
Ariel Esteban Bardach, Osvaldo Ulises Garay, María Calderón, Andrés Pichón-Riviére, Federico Augustovski, Sebastián García Martí, Paula Cortiñas, Marino Gonzalez, Laura T. Naranjo, Jorge Alberto Gomez & Joaquín Enzo Caporale. (2017) Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model. BMC Public Health 17:1.
Crossref
Crossref
Hyoung Jin Kim & Hong-Jin Kim. (2017) Current status and future prospects for human papillomavirus vaccines. Archives of Pharmacal Research 40:9, pages 1050-1063.
Crossref
Crossref
Lamb F, Herweijer E, Ploner A, Uhnoo I, Sundström K, Sparén P & Arnheim-Dahlström L. (2017) Timing of two versus three doses of quadrivalent HPV vaccine and associated effectiveness against condyloma in Sweden: a nationwide cohort study. BMJ Open 7:6, pages e015021.
Crossref
Crossref
Li-Min HuangThanyawee PuthanakitChiu Cheng-Hsun, Tang Ren-BinTino SchwarzAngelo PellegrinoSusanna EspositoLouise FrenetteShelly McNeilPaolo Durando, Paul Rheault, Carlo GiaquintoMichael HornKarl Ulrich PetryKlaus Peters, Toma AzharPeter HillemannsStephanie De Simoni, Damien Friel, Suryakiran Pemmaraju, Marjan Hezareh, Florence Thomas, Dominique Descamps, Nicolas Folschweiller & Frank Struyf. (2017) Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9–14 Years: A Randomized Trial. The Journal of Infectious Diseases 215:11, pages 1711-1719.
Crossref
Crossref
Robert A. Smith, Kimberly S. Andrews, Durado Brooks, Stacey A. Fedewa, Deana Manassaram-Baptiste, Debbie Saslow, Otis W. Brawley & Richard C. Wender. (2017) Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening. CA: A Cancer Journal for Clinicians 67:2, pages 100-121.
Crossref
Crossref
E. Meites, A. Kempe & L.E. Markowitz. (2017) Use of a 2-Dose Schedule for Human Papillomavirus Vaccination—Updated Recommendations of the Advisory Committee on Immunization Practices. American Journal of Transplantation 17:3, pages 834-837.
Crossref
Crossref
Elissa Meites, Allison Kempe & Lauri E. Markowitz. (2016) Use of a 2-Dose Schedule for Human Papillomavirus Vaccination — Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR. Morbidity and Mortality Weekly Report 65:49, pages 1405-1408.
Crossref
Crossref
Ligia A. Pinto, Troy J. Kemp, B. Nelson Torres, Kimberly Isaacs-Soriano, Donna Ingles, Martha Abrahamsen, Yuanji Pan, Eduardo Lazcano-Ponce, Jorge Salmeron & Anna R. Giuliano. (2016) Quadrivalent Human Papillomavirus (HPV) Vaccine Induces HPV-Specific Antibodies in the Oral Cavity: Results From the Mid-Adult Male Vaccine Trial. Journal of Infectious Diseases 214:8, pages 1276-1283.
Crossref
Crossref
Jean-François Laprise, Lauri E. Markowitz, Harrell W. Chesson, Mélanie Drolet & Marc Brisson. (2016) Comparison of 2-Dose and 3-Dose 9-Valent Human Papillomavirus Vaccine Schedules in the United States: A Cost-effectiveness Analysis. Journal of Infectious Diseases 214:5, pages 685-688.
Crossref
Crossref
Thanyawee Puthanakit, Li-Min Huang, Cheng-Hsun Chiu, Ren-Bin Tang, Tino F. Schwarz, Susanna Esposito, Louise Frenette, Carlo Giaquinto, Shelly McNeil, Paul Rheault, Paolo Durando, Michael Horn, Maximilian Klar, Sylviane Poncelet, Stéphanie De Simoni, Damien Friel, Benoit De Muynck, Pemmaraju V. Suryakiran, Marjan Hezareh, Dominique Descamps, Florence Thomas & Frank Struyf. (2016) Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9–14 Years Versus a 3-Dose Regimen in Women Aged 15–25 Years. Journal of Infectious Diseases 214:4, pages 525-536.
Crossref
Crossref
Julia M.L. Brotherton, Mark Jit, Patti E. Gravitt, Marc Brisson, Aimée R. Kreimer, Sara I. Pai, Carole Fakhry, Joseph Monsonego & Silvia Franceschi. (2016) Eurogin Roadmap 2015: How has HPV knowledge changed our practice: Vaccines. International Journal of Cancer 139:3, pages 510-517.
Crossref
Crossref
Margaret Stanley. (2016) HPV vaccines: how many doses are needed for protection?. Future Virology 11:4, pages 283-292.
Crossref
Crossref
Julia M. L. Brotherton & Paul J. N. Bloem. (2015) HPV Vaccination: Current Global Status. Current Obstetrics and Gynecology Reports 4:4, pages 220-233.
Crossref
Crossref